| Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes. | |
| | |
MedLine Citation:
|
PMID: 21067505 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Diabetic kidney disease is the leading cause of end-stage renal disease worldwide. Podocytes are highly differentiated, pericyte-like cells that are essential for normal function of the kidney filter. Loss of podocytes is a hallmark of progressive kidney diseases including diabetic nephropathy. Podocytes are a direct target for angiotensin II - mediated injury by altered expression and distribution of podocyte proteins. Additionally, angiotensin II promotes podocyte injury indirectly by increasing calcium influx and production of reactive oxygen species. Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). Recently published clinical trials have rekindled a debate on the safety and efficacy of dual blockade of the renin-angiotensin system (RAS). This review summarizes the rationale for blockade of angiotensin II as a therapeutic target in treating diabetic kidney disease, including the critical role played by podocytes. Recent relevant clinical trials on the role of RAS blockade in the treatment of diabetic kidney disease are discussed. |
| | |
Authors:
|
Kirk N Campbell; Leopoldo Raij; Peter Mundel |
Related Documents
:
|
6715765 - Low triiodothyronine and raised reverse triiodothyronine levels in patients over fifty ... 1743805 - Influence of type i and type ii diabetes mellitus on phenytoin steady-state levels. 2240915 - Slow glucose removal rate and hyperinsulinemia precede the development of type ii diabe... 10986155 - Impact of angiotensin ii on the kidney: does an angiotensin ii receptor blocker make se... 1673485 - Somatostatin-14 blocks the hepatotrophic effects of insulin in the rat. 8129495 - Early diabetic nephropathy. emerging treatment options. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current diabetes reviews Volume: 7 ISSN: 1875-6417 ISO Abbreviation: Curr Diabetes Rev Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-29 Completed Date: 2011-04-27 Revised Date: 2011-07-08 |
Medline Journal Info:
|
Nlm Unique ID: 101253260 Medline TA: Curr Diabetes Rev Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 3-7 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Leonard Miller School of Medicine, University of Miami, 1580 NW 10th Avenue, Miami, FL 33136, USA. kcampbell@med.miami.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin II
/
genetics,
metabolism,
physiology* Animals Diabetic Nephropathies / etiology*, genetics, pathology Humans Models, Biological Oxidative Stress / physiology Podocytes / pathology* |
| Chemical | |
Reg. No./Substance:
|
11128-99-7/Angiotensin II |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Estrogens and progression of diabetic kidney damage.
Next Document: Endocrinological aspects of proteinuria and podocytopathy in diabetes: role of the aldosterone/miner...